Vertex Pharmaceuticals Inc (MIL:1VRTX)
€ 436.75 0 (0%) Market Cap: 114.49 Bil Enterprise Value: 109.92 Bil PE Ratio: 0 PB Ratio: 7.74 GF Score: 72/100

Vertex Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) Transcript

Mar 02, 2021 / 02:50PM GMT
Philip M. Nadeau
Cowen and Company, LLC, Research Division - MD & Senior Research Analyst

Good morning and welcome once again to Cowen and Company's hopefully only virtual health care conference. I'm Phil Nadeau, a biotech analyst here at Cowen, and it's my pleasure to moderate a fireside chat with Vertex Pharmaceuticals. Those of you who follow our research know that Vertex is one of our top large-cap picks for this year.

So we're very happy to have with us this morning President and CEO, Reshma Kewalramani. And we'll spend about 30 minutes talking through the fundamentals of the company.

Reshma, maybe you could start with giving a brief state-of-the-company overview, the biggest strengths, biggest challenges and what you think needs to happen to create shareholder value in Vertex's stock over the next year.

Reshma Kewalramani
Vertex Pharmaceuticals Incorporated - CEO, President & Director

Good morning, Phil. It's really good to see you, and thank you for having me here today. Maybe I'll give you a thumbnail and just walk you

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot